Thomas Powles
Queen Mary University of London · Barts Cancer Center, Barts and The London School of Medicine and Denistry · Queen Mary University of London, UK
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Thomas Powles as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04878250 · Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the BladderQueen Mary University of London · unknown · Transitional Cell Carcinoma, Bladder Cancer · principal investigator
- Ph2NCT04624399 · Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial CancerQueen Mary University of London · completed · Urogenital Cancer · principal investigator
- Ph2NCT02662309 · Preoperative MPDL3280A in Transitional Cell Carcinoma of the BladderQueen Mary University of London · completed · Bladder Cancer · principal investigator
- Ph1NCT02546661 · Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerAstraZeneca · active not recruiting · Muscle Invasive Bladder Cancer · principal investigator
- Ph2NCT01793636 · A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal CancerQueen Mary University of London · terminated · Metastatic Clear Cell Renal Carcinoma · principal investigator
- Ph1NCT01714765 · Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal CancerQueen Mary University of London · completed · Metastatic Clear Cell Renal Cancer · principal investigator
- Ph2NCT01024205 · Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney CancerBarts and the London School of Medicine and Dentistry · completed · Kidney Cancer · principal investigator
- Ph2/Ph3NCT00949455 · A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the UrotheliumQueen Mary University of London · unknown · Bladder Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:45 UTC. The ranking covers the 200 most relevant of 282 PubMed records, and a shared surname and initials can bring in a namesake. All 282 on PubMed
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.N Engl J Med · 20183,807 citationsRCR 135.1
- 2,988 citationsRCR 94.8
- 2,795 citationsRCR 104.7
- 1,818 citationsRCR 57.2
- 1,521 citationsRCR 81.5
- 1,503 citationsRCR 81.7
- 1,234 citationsRCR 50.4
- 1,141 citationsRCR 38.0
- 1,070 citationsRCR 34.1
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.N Engl J Med · 20211,062 citationsRCR 59.5